Liquidia Co. (NASDAQ:LQDA) Insider Sells $31,785.00 in Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,445 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the sale, the insider now directly owns 267,943 shares of the company’s stock, valued at $3,483,259. The trade was a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Rajeev Saggar also recently made the following trade(s):

• On Tuesday, January 14th, Rajeev Saggar sold 6,249 shares of Liquidia stock. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $14.36 on Friday. The stock has a market capitalization of $1.22 billion, a PE ratio of -8.81 and a beta of 0.23. Liquidia Co. has a one year low of $8.26 and a one year high of $16.99. The business’s fifty day moving average price is $11.65 and its 200-day moving average price is $11.09.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC lifted its stake in shares of Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after buying an additional 9,984 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in Liquidia during the 3rd quarter valued at $100,000. Ballentine Partners LLC bought a new stake in Liquidia during the 3rd quarter valued at $110,000. Whitcomb & Hess Inc. boosted its holdings in shares of Liquidia by 10.2% in the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after acquiring an additional 1,074 shares during the period. Finally, Walleye Trading LLC grew its position in shares of Liquidia by 54.7% in the third quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after purchasing an additional 4,670 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

LQDA has been the topic of several analyst reports. Wells Fargo & Company began coverage on shares of Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. Lifesci Capital began coverage on Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective on the stock. Finally, Scotiabank started coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).